BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

A prototype nanoparticle biosensor based on localized surface plasmon resonance (LSPR) spectroscopy was developed to detect drug binding to human membrane-bound cytochrome P450 3A4 (CYP3A4). CYP3A4 is ...

UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency DisorderPhase 3 study met primary and key secondary clinical endpoints, marking the third developmental and ...

Amlodipine Amlodipine is a substrate of CYP3A4, and its plasma concentrations may be affected by inhibitors or inducers of this enzyme.

a HIV = human immunodeficiency virus, NRTI = nucleoside reverse transcriptase inhibitor, NNRTI = nonnucleoside reverse transcriptase inhibitor, PI = protease inhibitor. b While this has not been ...

During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works ...

The study concluded that strong CYP3A4 inhibitors and inducers should be avoided during treatment with ibrutinib because their significant impact on its pharmacokinetics could lead to AEs from ...

Covalent binding of reactive metabolites to cytochrome P450s (P450s) often causes their mechanism-based inactivation (MBI), resulting in drug–drug interactions or toxicity. The detection and ...